Jean-Mathieu Beauregard
Chercheur universitaire clinicien
Axe Oncologie
Radiologie, médecine nucléaire et imagerie médicale
Oncologie clinique
Publications
View all-
article Beauregard JM, Ong M, Pouliot F
How will PLUDO, PSMAfore, SPLASH, and ECLIPSE Impact Prostate Cancer Management
Eur Urol Focus 2026.
-
article Pouliot F, Lodde M, Besançon M, Castonguay V, Morin-Coulombe A, Fradet V, Fradet Y, Lacombe L, Lévesque É and Marcoux N, Toren P, April G, Arsenault F, Beaulieu A, Singbo N, Veilleux C, Tremblay-Boily M, Tremblay V, Buteau FA, Beauregard JM
Trajectory timelines and treatment efficacy of 177Lu-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer: Real-world data from 50 consecutive cases t…
Can Urol Assoc J 20 (6), 2026.
-
article Zamanian A, Rousseau É and Buteau FA, Arsenault F, Beaulieu A, April G, Juneau D, Plouznikoff N, Turcotte ÉE, Allard C, Richard PO, Saad F, Guérin B, Pouliot F, Beauregard JM
The tumour sink effect on 68Ga-PSMA-PET/CT in metastatic castration-resistant prostate cancer and its implications for PSMA-RPT: a sub-analysis of the 3TMPO study
Cancer Imaging 25 (1), 2025.
Projects
- Towards Personalized Dosimetry-Based Radioligand Therapy of Prostate Cancer as a New Standard of Practice, from 2022-04-01 to 2027-03-31
- Tirer profit des données de soins en contexte réel pour une introduction responsable, efficiente et équitable des innovations thérapeutiques en oncologie : la plateforme MEDOnco-VieRéelle, from 2024-09-01 to 2027-08-31
- Enhancing the PARADIM platform to bridge the gap between data and AI in medical imaging, from 2024-09-01 to 2027-08-31
- Les agents theranostiques: anticorps monoclonaux conjugués au médicament et marqués aux radioisotopes 89Zr/225Ac contre le récepteur du facteur de croissance épidermique des cancers colorectal- essai clinique prometteur, from 2024-09-01 to 2027-10-31
- Randomized-controlled, single-blind, pilot study of personalized vs. empiric PSMA-RLT (CAAA617A12102T), from 2025-06-06 to 2030-12-25
- 161Tb/225Ac-labeled anti-Nectin-4 radioimmunoconjugates with/without immune checkpoint inhibitors against NSCLC, from 2025-04-01 to 2030-03-30
- Development of GMP-grade anti-Nectin-4 radioimmunoconjugates, and clinical trial enabling studies for phase 1 trial against Nectin-4 positive NSCLC and TNBC, from 2025-03-11 to 2028-02-29
- Identifying the subgroups of GEP-NET patients that could benefit from temozolomide-induced upregulation of SSTR2 prior to PRRT, from 2025-06-01 to 2027-05-31
- Development of GMP-grade anti-Nectin-4 radioimmunoconjugates, and clinical trial enabling studies for phase 1 trial against Nectin-4-positive NSCLC and TNBC, from 2025-09-26 to 2028-09-25
- Development of GMP-grade anti-Nectin-4 radioimmunoconjugates, and clinical trial enabling studies for phase 1 trial against Nectin-4 positive NSCLC and TNBC, from 2025-10-01 to 2028-09-30
- Installation centrale d'imagerie moléculaire préclinique, from 2026-03-24 to 2027-09-30
- 4-Timepoint Multi-tracer PET imaging to characterize prOstate Cancer heterogeneity (4TMPO), from 2026-04-01 to 2029-03-31
- Potentiation of PRRT by chemotherapy-mediated upregulation of somatostatin receptor 2 in NET cell lines-derived tumors in mice and in Lung NET patient-derived tumor explants, from 2022-04-01 to 2024-12-31
- Équipement de laboratoire radiopharmaceutique pour la théranostique et l'imagerie moléculaire innovantes, from 2022-07-01 to 2026-03-31
- Screening of gastroenteropancreatic neuroendocrine tumors from patients for temozolomide-induced upregulation of SSTR2: Towards improved PRRT, from 2023-04-01 to 2025-12-31